Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Zura Bio Limited (NASDAQ: ZURA) had its price target lowered by analysts at Chardan Capital from $14.00 to $12.00. They now have a "buy" rating on the stock.
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Zura Bio Limited (NASDAQ: ZURA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.